What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
His primary areas of study are Internal medicine, Oncology, Surgery, Chemotherapy and Bladder cancer.
His work deals with themes such as Combination chemotherapy and Proportional hazards model, which intersect with Oncology.
His Surgery research integrates issues from Prostate cancer and Urology.
He has researched Prostate cancer in several fields, including Docetaxel and Intensive care medicine.
His biological study spans a wide range of topics, including Urothelium and Standard treatment.
His Bladder cancer research incorporates themes from Cancer research, Urinary bladder and Disease.
His most cited work include:
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial (1967 citations)
- EAU–ESTRO–SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent (1873 citations)
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer (1641 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Oncology, Chemotherapy, Bladder cancer and Surgery.
Internal medicine is a component of his Cancer, Docetaxel, Prostate cancer, Metastatic Urothelial Carcinoma and Renal cell carcinoma studies.
His study looks at the intersection of Oncology and topics like Cisplatin with Gemcitabine.
His Chemotherapy research includes elements of Pembrolizumab, Urothelial cancer and Regimen.
His research in Bladder cancer tackles topics such as Cancer research which are related to areas like Pathology.
His work carried out in the field of Surgery brings together such families of science as Gastroenterology and Hazard ratio.
He most often published in these fields:
- Internal medicine (69.39%)
- Oncology (62.23%)
- Chemotherapy (26.60%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (69.39%)
- Oncology (62.23%)
- Bladder cancer (24.72%)
In recent papers he was focusing on the following fields of study:
Joaquim Bellmunt mostly deals with Internal medicine, Oncology, Bladder cancer, Chemotherapy and Metastatic Urothelial Carcinoma.
In his work, he performs multidisciplinary research in Internal medicine and In patient.
His Oncology study also includes fields such as
- Cisplatin which is related to area like Combination chemotherapy,
- Avelumab which intersects with area such as Maintenance therapy.
His Bladder cancer research includes themes of Adjuvant chemotherapy, Proportional hazards model, Disease and Urology.
As part of one scientific family, he deals mainly with the area of Chemotherapy, narrowing it down to issues related to the Hazard ratio, and often Interquartile range.
His study in Metastatic Urothelial Carcinoma is interdisciplinary in nature, drawing from both Cancer research, Atezolizumab, PD-L1, Carcinoma and Survival analysis.
Between 2017 and 2021, his most popular works were:
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (174 citations)
- A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. (167 citations)
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma (100 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Oncology, Bladder cancer, Chemotherapy and Metastatic Urothelial Carcinoma are his primary areas of study.
His work is connected to Pembrolizumab, Clinical trial, Docetaxel, Atezolizumab and Clinical endpoint, as a part of Internal medicine.
His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Cisplatin, Phases of clinical research, First line and Cohort.
He has included themes like Proportional hazards model, Disease and Immunotherapy in his Bladder cancer study.
His research in Chemotherapy intersects with topics in Erdafitinib, Interim analysis, Regimen and Hazard ratio.
His studies in Metastatic Urothelial Carcinoma integrate themes in fields like PD-L1, Carcinoma, Survival analysis and Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
